| Year |
Citation |
Score |
| 2023 |
Patton AP, Morris EL, McManus D, Wang H, Li Y, Chin JW, Hastings MH. Astrocytic control of extracellular GABA drives circadian timekeeping in the suprachiasmatic nucleus. Proceedings of the National Academy of Sciences of the United States of America. 120: e2301330120. PMID 37186824 DOI: 10.1073/pnas.2301330120 |
0.335 |
|
| 2021 |
Morris EL, Patton AP, Chesham JE, Crisp A, Adamson A, Hastings MH. Single-cell transcriptomics of suprachiasmatic nuclei reveal a Prokineticin-driven circadian network. The Embo Journal. e108614. PMID 34487375 DOI: 10.15252/embj.2021108614 |
0.343 |
|
| 2012 |
Smarr BL, Morris E, de la Iglesia HO. The dorsomedial suprachiasmatic nucleus times circadian expression of Kiss1 and the luteinizing hormone surge. Endocrinology. 153: 2839-50. PMID 22454148 DOI: 10.1210/en.2011-1857 |
0.373 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Field AC, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N, Stauss H, Thrasher A, Morris E, Qasim W. Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer. Plos One. 8: e68201. PMID 23840834 DOI: 10.1371/journal.pone.0068201 |
0.161 |
|
| 2007 |
Thomas S, Xue SA, Cesco-Gaspere M, San José E, Hart DP, Wong V, Debets R, Alarcon B, Morris E, Stauss HJ. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. Journal of Immunology (Baltimore, Md. : 1950). 179: 5803-10. PMID 17947653 DOI: 10.4049/Jimmunol.179.9.5803 |
0.159 |
|
| 2018 |
Khan AB, Carpenter B, Sousa PSE, Pospori C, Khorshed R, Griffin J, Veliça P, Zech M, Ghorashian S, Forrest C, Thomas S, Anton SG, Ahmadi M, Holler A, Flutter B, ... ... Morris E, et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. The Journal of Clinical Investigation. PMID 29485974 DOI: 10.1172/JCI97454 |
0.158 |
|
| 2005 |
Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 106: 3062-7. PMID 16020516 DOI: 10.1182/blood-2005-01-0146 |
0.154 |
|
| 2008 |
Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells, Molecules & Diseases. 40: 113-6. PMID 17855129 DOI: 10.1016/j.bcmd.2007.06.018 |
0.149 |
|
| 2011 |
Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ. CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 118: 3528-37. PMID 21750319 DOI: 10.1182/blood-2011-04-346338 |
0.147 |
|
| 2017 |
Chen Y, Xue SA, Mohammad GH, Pereira SP, Morris E, Behboudi S. Ex vivo PD-L1/PD-1 pathway blockade reverses dysfunction of circulating CEA specific T cells in pancreatic cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28710313 DOI: 10.1158/1078-0432.CCR-17-1185 |
0.14 |
|
| 2017 |
Gohil SH, Paredes-Moscosso SR, Harrasser M, Vezzalini M, Scarpa A, Morris E, Davidoff AM, Sorio C, Nathwani AC, Della Peruta M. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. Oncoimmunology. 6: e1326437. PMID 28811962 DOI: 10.1080/2162402X.2017.1326437 |
0.138 |
|
| 2022 |
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, ... ... Morris E, et al. Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? Journal For Immunotherapy of Cancer. 10. PMID 35577501 DOI: 10.1136/jitc-2021-003487 |
0.137 |
|
| 2006 |
Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell therapies. Blood Reviews. 20: 61-9. PMID 15978709 DOI: 10.1016/j.blre.2005.05.001 |
0.132 |
|
| 2020 |
Xue SA, Chen Y, Voss RH, Kisan V, Wang B, Chen KK, He FQ, Cheng XX, Scolamiero L, Holler A, Gao L, Morris E, Stauss HJ. Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing. Cellular & Molecular Immunology. PMID 32203185 DOI: 10.1038/s41423-020-0396-9 |
0.129 |
|
| 2015 |
Ghorashian S, Veliça P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA, Uckert W, Morris E, Chakraverty R, Stauss HJ. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. Journal of Immunology (Baltimore, Md. : 1950). 194: 1080-9. PMID 25539815 DOI: 10.4049/jimmunol.1401703 |
0.128 |
|
| 2023 |
Alrubayyi A, Touizer E, Hameiri-Bowen D, Charlton B, Gea-Mallorquí E, Hussain N, da Costa KAS, Ford R, Rees-Spear C, Fox TA, Williams I, Waters L, Barber TJ, Burns F, Kinloch S, ... Morris E, et al. Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1. Scientific Reports. 13: 18994. PMID 37923825 DOI: 10.1038/s41598-023-45412-9 |
0.127 |
|
| 2022 |
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, ... ... Morris E, et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. Journal For Immunotherapy of Cancer. 10. PMID 35577500 DOI: 10.1136/jitc-2021-003486 |
0.125 |
|
| 2010 |
Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 95: 126-34. PMID 19679884 DOI: 10.3324/haematol.2009.006486 |
0.12 |
|
| 2022 |
Touizer E, Alrubbayi A, Ford R, Hussain N, Gerber PP, Shum HL, Rees-Spear C, Muir L, Gea-Mallorquí E, Kopycinski J, Jankovic D, Pinder C, Fox TA, Williams I, Mullender C, ... ... Morris E, et al. Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles. Biorxiv : the Preprint Server For Biology. PMID 36380764 DOI: 10.1101/2022.11.11.516111 |
0.118 |
|
| 2009 |
Cesco-Gaspere M, Morris E, Stauss HJ. Immunomodulation in the treatment of haematological malignancies. Clinical and Experimental Medicine. 9: 81-92. PMID 19238515 DOI: 10.1007/s10238-009-0037-1 |
0.118 |
|
| 2015 |
Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, Exley MA, Stauss H, Maher J, Pule M, Sewell AK, Bendle G, Lee S, Qasim W, Thrasher A, Morris E. Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Human Gene Therapy. 26: 276-85. PMID 25860661 DOI: 10.1089/Hum.2015.024 |
0.105 |
|
| 2010 |
Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 1419-27. PMID 20399879 DOI: 10.1016/j.bbmt.2010.04.006 |
0.105 |
|
| 2014 |
Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hämäläinen S, Seppänen M, Helbert M, ... ... Morris E, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 123: 863-74. PMID 24345756 DOI: 10.1182/Blood-2013-07-517151 |
0.103 |
|
| 2022 |
Touizer E, Alrubayyi A, Ford R, Hussain N, Gerber PP, Shum HL, Rees-Spear C, Muir L, Gea-Mallorquí E, Kopycinski J, Jankovic D, Jeffery-Smith A, Pinder CL, Fox TA, Williams I, ... ... Morris E, et al. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. Iscience. 26: 105862. PMID 36590902 DOI: 10.1016/j.isci.2022.105862 |
0.103 |
|
| 2009 |
Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Transplantation. 88: 1312-8. PMID 19996931 DOI: 10.1097/TP.0b013e3181bbf382 |
0.102 |
|
| 2015 |
Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Journal of Hepatology. 62: 486-91. PMID 25308176 DOI: 10.1016/J.Jhep.2014.10.001 |
0.1 |
|
| 2017 |
Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding A, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, ... ... Morris E, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. PMID 29279357 DOI: 10.1182/blood-2017-09-807487 |
0.096 |
|
| 2012 |
Loosemore M, Walsh SB, Morris E, Stewart G, Porter JB, Montgomery H. Sudden exertional death in sickle cell trait. British Journal of Sports Medicine. 46: 312-4. PMID 21965838 DOI: 10.1136/bjsports-2011-090521 |
0.094 |
|
| 2020 |
Cuadrado MM, Szydlo RM, Watts M, Patel N, Renshaw H, Dorman J, Lowdell M, Ings S, Anthias C, Madrigal A, Mackinnon S, Kottaridis P, Carpenter B, Hough R, Morris E, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 105: 2639-2646. PMID 33131253 DOI: 10.3324/haematol.2019.226340 |
0.093 |
|
| 2020 |
Leiper A, Houwing M, Davies EG, Rao K, Burns S, Morris E, Laven J, van der Kooi AL, van den Heuvel Eibrink M, Nussey S. Correction: Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens. Bone Marrow Transplantation. PMID 32332919 DOI: 10.1038/s41409-020-0914-5 |
0.088 |
|
| 2013 |
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology. 160: 640-8. PMID 23293871 DOI: 10.1111/bjh.12197 |
0.086 |
|
| 2004 |
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 104: 3865-71. PMID 15304395 DOI: 10.1182/BLOOD-2004-03-1105 |
0.085 |
|
| 2015 |
Verrill C, Cerundolo L, Mckee C, White M, Kartsonaki C, Fryer E, Morris E, Brewster S, Ratnayaka I, Marsden L, Lilja H, Muschel R, Lu X, Hamdy F, Bryant RJ. Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. Oncotarget. PMID 26701730 DOI: 10.18632/Oncotarget.6689 |
0.078 |
|
| 2020 |
Leiper A, Houwing M, Davies EG, Rao K, Burns S, Morris E, Laven J, van der Kooi AL, van den Heuvel Eibrink M, Nussey S. Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens. Bone Marrow Transplantation. PMID 32231250 DOI: 10.1038/s41409-020-0866-9 |
0.078 |
|
| 2010 |
Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, ... ... Morris E, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 116: 3080-8. PMID 20587785 DOI: 10.1182/blood-2010-05-286856 |
0.077 |
|
| 2005 |
Morris E, Mackinnon S. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) Transfusion and Apheresis Science. 32: 73-83. PMID 15737876 DOI: 10.1016/j.transci.2004.10.008 |
0.075 |
|
| 2014 |
Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. British Journal of Haematology. 165: 334-40. PMID 24438080 DOI: 10.1111/bjh.12741 |
0.066 |
|
| 2014 |
Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. Plos One. 9: e88133. PMID 24520352 DOI: 10.1371/journal.pone.0088133 |
0.066 |
|
| 2013 |
Morris E, Gore M, Baker A, Thrasher AJ. Moving forward on shifting sands: ethical regulation of gene therapy clinical trials in the United kingdom. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 715-6. PMID 23542562 DOI: 10.1038/mt.2013.43 |
0.052 |
|
| 2004 |
Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS. Reduced intensity transplantation: where are we now? The Hematology Journal : the Official Journal of the European Haematology Association. S34-8. PMID 15190275 DOI: 10.1038/SJ.THJ.6200419 |
0.049 |
|
| 2011 |
Morris E, Milner P, Trower P, Peters E. Clinical presentation and early care relationships in 'poor-me' and 'bad-me' paranoia. The British Journal of Clinical Psychology / the British Psychological Society. 50: 211-6. PMID 21545452 DOI: 10.1348/014466510X525498 |
0.047 |
|
| 2020 |
Kozyra EJ, Pastor VB, Lefkopoulos S, Sahoo SS, Busch H, Voss RK, Erlacher M, Lebrecht D, Szvetnik EA, Hirabayashi S, Pasaulienė R, Pedace L, Tartaglia M, Klemann C, Metzger P, ... ... Morris E, et al. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. Leukemia. PMID 32555368 DOI: 10.1038/s41375-020-0899-5 |
0.04 |
|
| 2023 |
Midgley N, Mortimer R, Carter M, Casey P, Coffman L, Edbrooke-Childs J, Edridge C, Fonagy P, Gomes M, Kapoor A, Marks S, Martin P, Moltrecht B, Morris E, Pokorna N, et al. Emotion regulation in children (ERiC): A protocol for a randomised clinical trial to evaluate the clinical and cost effectiveness of Mentalization Based Treatment (MBT) vs Treatment as Usual for school-age children with mixed emotional and behavioural difficulties. Plos One. 18: e0289503. PMID 37590277 DOI: 10.1371/journal.pone.0289503 |
0.039 |
|
| 2004 |
Iqbal Z, Birchwood M, Hemsley D, Jackson C, Morris E. Autobiographical memory and post-psychotic depression in first episode psychosis. The British Journal of Clinical Psychology. 43: 97-104. PMID 15005909 DOI: 10.1348/014466504772812995 |
0.013 |
|
| 2014 |
Morris E, Le Huray C, Skagerberg E, Gomes R, Ninteman A. Families changing families: the protective function of multi-family therapy for children in education. Clinical Child Psychology and Psychiatry. 19: 617-32. PMID 23838692 DOI: 10.1177/1359104513493429 |
0.01 |
|
| Hide low-probability matches. |